查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715684

动物疫苗市场按产品类型、动物类型、疾病类型、给药途径和分销管道划分－2025-2030 年全球预测

Animal Vaccines Market by Product, Animal Type, Disease Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计兽用疫苗市场规模到 2024 年将达到 136.9 亿美元，到 2025 年将达到 145.8 亿美元，到 2030 年将达到 202.7 亿美元，复合年增长率为 6.75%。

主要市场统计数据
基准年2024年 136.9亿美元
预计2025年 145.8亿美元
预测年份 2030 202.7亿美元
复合年增长率（%） 6.75%

近年来，随着人们对动物健康、食品安全和公共的认识不断提高，兽用疫苗市场已成为全球卫生领域的重要领域。本报告深入探讨了重塑该行业的演变趋势、技术进步和战略要务。科学、法规和市场需求的动态相互作用正在创造机会和挑战，需要产品创新和对宿主生物学的敏锐理解。本介绍概述了关键主题，包括新型疫苗开发的作用、可靠的临床数据的重要性以及影响市场采用的监管变化。疫苗输送方法和製剂技术的不断改进代表着变革时期，它正在重新定义兽医和牲畜管理者如何进行预防性动物保健。深入研究这项综合分析将阐明当前的实践和未来的成长前景，帮助决策者根据新兴市场讯号调整他们的策略。

全球兽用疫苗领域的特点是研发活动不断增加、先进生物技术的整合和策略联盟不断加强。这些趋势不仅刺激了创新，而且扩大了可用疫苗产品的范围。当相关人员应对监管复杂性和竞争压力时，了解这些变化对于使投资和营运重点与长期市场现实保持一致至关重要。

市场动态正在变革时期

兽用疫苗市场目前正处于变革时期，正在重塑产业动态并重新定义竞争格局。新技术为敏捷製造流程铺平了道路，大大缩短了新型疫苗候选物的上市时间。基因工程和生物技术的关键进展凸显了从传统疫苗配方转向 mRNA 和重组疫苗等创新方法的转变。这种转变不仅受到科学突破的推动，也受到强调功效、安全性和对疾病爆发的快速反应的不断发展的法律规范的推动。

投资模式也发生了显着变化，研发资金的增加使得兽医疫苗接种方法更加个人化。产业相关人员目前正在利用数据分析和尖端诊断工具来评估不同动物物种的特定疾病特征，从而找到更有针对性的疫苗解决方案。此外，数位健康平台的整合增强了监测疫苗接种后结果的能力，确保现实世界的疗效支持临床试验的声明。这种数位转型正在创造一个持续反馈和自适应製造成为常态的环境，支援更具弹性和反应能力的供应链。

人们也越来越重视研究机构、生物製药公司和兽医师之间的合作。这种合作对于利用综合专业知识将科学转化为可行的市场解决方案至关重要。最终，向更技术化和数据化的行业转变凸显了长期改善动物健康、降低风险和实现更永续的疫苗市场的潜力。

深入了解动物疫苗的关键领域

对兽用疫苗市场的详细分析揭示了多种细分策略，以了解该行业的多样性和深度。特别值得注意的是产品细分，其涵盖频谱广泛，包括灭活疫苗、减毒活病毒疫苗、mRNA疫苗、重组疫苗和次单位疫苗。这些分类代表了旨在优化不同物种免疫反应的技术进步和复杂的製造过程。产品配置的多样化使相关人员能够满足特殊需求并针对其各自的动物健康挑战制定解决方案。

此外，基于动物类型的细分提供了进一步的市场洞察。市场分为伴同性动物和牲畜，前者主要以猫和狗为代表，后者包括牛、家禽、羊和猪，每种动物都有不同的需求模式和监管要求。这种细分考虑了疫苗管理通讯协定的差异以及每个细分领域不同的经济考量。例如，伴同性动物疫苗通常由饲主的偏好和预防性健康措施驱动，而牲畜疫苗必须符合严格的食品安全标准和生物安全法规。

基于疾病类型的分割透过关注细菌、真菌、寄生虫和病毒感染增加了额外的粒度层。在此框架内，细菌感染疾病进一步分为梭菌病、大肠桿菌病、钩端螺旋体病和巴氏桿菌症，而寄生虫感染疾病则分为外寄生虫和内寄生虫。病毒感染疾病涵盖几种重要病原体，包括禽流感病毒、牛病毒性腹泻病毒、口蹄疫病毒、新城疫病毒、猪隻繁殖与呼吸综合症病毒和狂犬病毒。这些详细的子类别显示了特定病原体和疫苗反应之间的相互作用如何推动临床、物流和金融领域的创新和市场区隔。

此外，对给药途径的分析可以深入了解疫苗设计的实际意义。疫苗分为注射疫苗和口服疫苗，注射疫苗的给药途径又分为肌肉注射、静脉注射和皮下注射。这个详细的市场区隔重点介绍了给药途径如何影响疫苗效力、依从性和整体市场渗透率。最后，分销管道的细分，包括线上药局、零售药局和兽医诊所，凸显了市场在维持传统实体分销网络的同时，正在适应数位转型。这些细分策略结合起来可以提供一个全面的框架来了解市场趋势，并帮助相关人员制定策略来有效满足不同动物物种和疾病特征的不同需求。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球通用感染疾病的盛行率不断上升
      • 政府推动全球动物保健的倡议
    • 限制因素
      • 动物疫苗研究、开发和生产高成本
    • 机会
      • 与野生动物保护组织建立新的伙伴关係
      • 疫苗输送创新增强了输送能力并改善了动物的免疫反应
    • 任务
      • 围绕动物疫苗的严格法规和核准程序
  • 市场区隔分析
    • 产品：减毒活病毒疫苗正日益成为防御病原生物学复杂的疾病的首选方法。
    • 动物类型：宠物拥有量的增加增加了伴侣动物兽医疫苗的重要性。
    • 疾病类型：抗病毒感染的动物疫苗需求不断增加
    • 给药途径：肌肉注射疫苗由于能快速被血液吸收，因此变得越来越重要
    • 分销管道：数位化平台的普及和便利性的提高推动了人们对网路药局的偏好
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章动物疫苗市场（依产品）

  • 灭活疫苗
  • 减毒活疫苗
  • mRNA疫苗
  • 重组疫苗
  • 次单位疫苗

7. 动物疫苗市场（依动物类型）

  • 伴同性动物
    • 猫
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 猪

第八章动物疫苗市场（依疾病类型）

  • 细菌感染疾病
    • 梭菌
    • 大肠桿菌
    • 钩端螺旋体病
    • 巴氏桿菌
  • 霉菌感染疾病
  • 寄生虫感染疾病
    • 体外寄生虫
    • 体内寄生虫
  • 病毒感染
    • 禽流感病毒
    • 牛病毒性腹泻病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 猪繁殖与呼吸综合症病毒（PRRSV）
    • 狂犬病毒

第九章动物疫苗市场（依给药途径）

  • 注射疫苗
    • 肌肉注射（IM）
    • 静脉注射（IV）
    • 皮下（SC）
  • 口服疫苗

第 10 章动物疫苗市场（依通路）

  • 网路药局
  • 零售药局
  • 兽医诊所

第 11 章：美洲动物疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太动物疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲动物疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Biogenesis Bago SA
  • BioVaxys Technology Corporation
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private limited
  • Ceva Sante Animale
  • China Animal Husbandry Industry Co., Ltd.
  • Dalan Animal Health
  • Elanco Animal Health Inc.
  • Endovac Animal Health, LLC by Immvac Inc.
  • Hester Biosciences Limited
  • HIPRA, SA
  • Indian Immunologicals Limited
  • Kemin Industries, Inc.
  • Merck KGaA
  • Neogen Corporation
  • Phibro Animal Health Corporation
  • SAN Vet Holding GmbH
  • Sanofi SA
  • Seppic SA
  • Torigen Pharmaceuticals Inc.
  • Vaxxinova GmbH
  • VEROVACCiNES GmbH
  • Vetigenics, LLC
  • Vetoquinol SA
  • Virbac, Inc.
  • Zoetis Inc.
Product Code: MRR-ED54C46E8F03

The Animal Vaccines Market was valued at USD 13.69 billion in 2024 and is projected to grow to USD 14.58 billion in 2025, with a CAGR of 6.75%, reaching USD 20.27 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 13.69 billion
Estimated Year [2025] USD 14.58 billion
Forecast Year [2030] USD 20.27 billion
CAGR (%) 6.75%

In recent years, the animal vaccines market has emerged as a critical segment within the global health landscape, driven by growing awareness of animal health, food security, and public safety. This report provides an in-depth exploration of the evolving trends, technological advancements, and strategic imperatives that are reshaping this sector. The dynamic interplay between science, regulation, and market demand is creating opportunities and challenges that require a keen understanding of product innovations and host biology. This introduction sets the stage by outlining key themes including the role of novel vaccine development, the importance of robust clinical data, and the regulatory shifts that influence market adoption. The ongoing improvements in vaccine delivery methods and formulation techniques signify a transformative period that is redefining how veterinarians and livestock managers approach preventive animal health care. As we delve further into this comprehensive analysis, the discussion will illuminate both current practices and future growth prospects, thereby enabling decision-makers to align their strategies with emerging market signals.

The global animal vaccines landscape is characterized by ever-increasing research and development activities, integration of advanced biotechnologies, and strategic collaborations. These trends are not only fostering innovation but are also expanding the breadth of available vaccine products. As stakeholders navigate through regulatory complexities and competitive pressures, understanding these shifts becomes critical for aligning investment and operational priorities with long-term market realities.

Transformative Shifts in Market Dynamics

The animal vaccines market is currently experiencing transformative shifts that are reshaping industry dynamics and redefining competitive landscapes. Emerging technologies have paved the way for agile manufacturing processes and have significantly reduced the time-to-market for novel vaccine candidates. With pivotal advancements in genetic engineering and biotechnology, there is a marked transition from traditional vaccine formulations to innovative approaches such as mRNA and recombinant vaccines. This transformation is not solely driven by scientific breakthroughs but is also influenced by evolving regulatory frameworks that emphasize efficacy, safety, and rapid deployment in response to disease outbreaks.

A notable shift is occurring in the investment patterns, where increased funding in research and development is enabling a more personalized approach to animal immunization. Industry stakeholders are now leveraging data analytics and cutting-edge diagnostic tools to assess the unique disease profiles of different animal species, leading to more targeted vaccine solutions. Furthermore, the integration of digital health platforms has enhanced the ability to monitor post-vaccination outcomes, ensuring that real-world efficacy supports clinical trial claims. This digital transition is creating an environment where continuous feedback and adaptive manufacturing become the norm, thereby supporting a more resilient and responsive supply chain.

The emphasis on collaborative ventures between research institutions, biopharmaceutical companies, and veterinary practitioners has also intensified. Such alliances are critical in harnessing collective expertise to translate science into viable market solutions. Ultimately, the shift towards a more technologically empowered and data-informed industry underscores the potential for improved animal health outcomes, risk minimization, and a more sustainable vaccine market in the long run.

Key Segmentation Insights in Animal Vaccines

A detailed analysis of the animal vaccines market reveals multiple segmentation strategies that provide a rich understanding of the sector's diversity and depth. The product segmentation is particularly noteworthy as it encompasses a broad spectrum including inactivated vaccines, live attenuated vaccines, mRNA vaccines, recombinant vaccines, and subunit vaccines. These classifications illustrate the technological advancements and complex manufacturing processes designed to optimize immune responses across various species. This diversification in product profile enables stakeholders to address specialised needs and tailor solutions that align with distinct animal health challenges.

Moreover, segmentation based on animal type further refines market insights. The market distinguishes between companion animals and livestock, where the former, represented mainly by cats and dogs, and the latter, including cattle, poultry, sheep, and swine, drive distinct demand patterns and regulatory requirements. Such segmentation accounts for the variability in vaccine administration protocols and the differing economic considerations that underpin each segment. For instance, while companion animal vaccines are often driven by pet owner preferences and preventive health measures, vaccines for livestock animals must align with stringent food safety standards and biosecurity regulations.

The segmentation based on disease types adds another layer of granularity by focusing on bacterial infections, fungal infections, parasitic infections, and viral infections. Within this framework, bacterial infections are further divided into clostridial, Escherichia coli, leptospirosis, and pasteurella, while parasitic infections differentiate between ectoparasites and endoparasites. The viral segment covers several critical pathogens including avian influenza, bovine viral diarrhea virus, foot-and-mouth disease virus, Newcastle disease virus, porcine reproductive and respiratory syndrome virus, and rabies virus. These detailed sub-categories illustrate how the interplay between specific pathogens and vaccine responses drives innovation and market segmentation in clinical, logistical, and financial realms.

Additionally, analysis of the route of administration offers insights into the practical implications of vaccine design. The classifications include injectable and oral vaccines, with injectable routes being further delineated into intramuscular, intravenous, and subcutaneous methods. This detailed breakdown emphasizes how the route of administration can influence vaccine efficacy, compliance, and overall market penetration. Finally, the distribution channel segmentation, which includes online pharmacies, retail pharmacies, and veterinary clinics, underlines the market's adaptation to digital transformation while maintaining traditional physical distribution networks. Together, these segmentation strategies provide a comprehensive framework to understand market trends and enable stakeholders to craft strategies that effectively address the heterogeneous needs of diverse animal species and disease profiles.

Based on Product, market is studied across Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, Recombinant Vaccines, and Subunit Vaccines.

Based on Animal Type, market is studied across Companion Animals and Livestock Animals. The Companion Animals is further studied across Cats and Dogs. The Livestock Animals is further studied across Cattle, Poultry, Sheep, and Swine.

Based on Disease Type, market is studied across Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections. The Bacterial Infections is further studied across Clostridial, E. Coli, Leptospirosis, and Pasteurella. The Parasitic Infections is further studied across Ectoparasites and Endoparasites. The Viral Infections is further studied across Avian Influenza Virus, Bovine Viral Diarrhea Virus (BVDV), Foot-and-Mouth Disease Virus (FMDV), Newcastle Disease Virus, Porcine Reproductive & Respiratory Syndrome Virus (PRRSV), and Rabies Virus.

Based on Route of Administration, market is studied across Injectable Vaccines and Oral Vaccines. The Injectable Vaccines is further studied across Intramuscular (IM), Intravenous (IV), and Subcutaneous (SC).

Based on Distribution Channel, market is studied across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics.

Key Global Regional Insights

The regional landscape of the animal vaccines market is marked by distinct geographic trends that reflect variations in economic development, regulatory environments, and consumer preferences. The Americas remain a robust market characterized by high investment in advanced biotechnologies and a proactive approach to animal health. Nations in this region have embraced innovation through substantial funding and supportive governmental policies, which in turn have fostered a dynamic environment for vaccine research and development.

In Europe, the Middle East, and Africa, there is an increasing focus on integrating modern manufacturing techniques with traditional vaccination approaches. This region is witnessing a blend of mature markets with emerging economies where modernization is gradually expanding the scope of animal health initiatives. Stakeholders are focusing on strengthening supply chains, establishing quality control measures, and leveraging regional partnerships to improve access to state-of-the-art vaccine products. These efforts are particularly significant in light of rising concerns around zoonotic diseases and the imperative for stringent health monitoring of livestock populations.

Asia-Pacific represents a rapidly evolving market driven by population growth, urbanization, and rising incomes. This region has seen a surge in demand for advanced vaccines, primarily driven by the expanding livestock sector and the growing popularity of companion animals. Significant investments in research and a burgeoning biopharmaceutical industry are fueling the adoption of innovative vaccine technologies. The interplay between traditional agricultural practices and modern health management strategies in this region is not only boosting vaccine uptake but is also creating new opportunities for market entrants. The regional analysis highlights variations in regulatory frameworks and investment trends, which underscore the importance of tailoring strategic initiatives to local contexts for sustained market growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Strategic Key Companies in the Sector

The competitive landscape in the animal vaccines market is defined by the contributions of several leading companies that are actively shaping trends through innovation and strategic collaborations. Prominent industry players such as Biogenesis Bago S.A. and BioVaxys Technology Corporation have carved out significant market positions by focusing on research-driven approaches and comprehensive solutions that cater to both companion and livestock animal segments. Companies like Boehringer Ingelheim International GmbH and Brilliant Bio Pharma Private Limited continue to define the cutting edge of clinical development with their robust portfolio of vaccine offerings.

Other influential organizations, including Ceva Sante Animale and China Animal Husbandry Industry Co., Ltd., have made substantial inroads in emerging markets by leveraging local expertise and agile manufacturing processes. Dalan Animal Health and Elanco Animal Health Inc. further exemplify the trend towards integrated solutions that merge innovative vaccine technologies with efficient distribution networks. Additionally, firms such as Endovac Animal Health LLC by Immvac Inc. and Hester Biosciences Limited are pushing the boundaries by harnessing novel biotechnology platforms to address emerging pathogens.

Companies like HIPRA, S.A. and Indian Immunologicals Limited are playing pivotal roles in expanding market reach and enhancing vaccine efficacy through targeted research initiatives. The strategic moves from Kemin Industries, Inc. and Merck KGaA have underscored the importance of global partnerships, while Neogen Corporation and Phibro Animal Health Corporation have further expanded their influence through targeted acquisitions and market-specific adaptations. SAN Vet Holding GmbH, Sanofi S.A., and Seppic S.A. stand out for their commitment to continuous innovation, even as Torigen Pharmaceuticals Inc., Vaxxinova GmbH, and VEROVACCiNES GmbH consolidate their presence through specialized product lines. These trends are complemented by the focused efforts of Vetigenics LLC, Vetoquinol SA, Virbac, Inc., and Zoetis Inc., whose diverse strategies emphasize targeted research, agile manufacturing, and an unwavering commitment to improving animal health on a global scale. Their contributions not only drive market innovation but also emphasize a commitment to quality, efficacy, and global health standards.

The report delves into recent significant developments in the Animal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Biogenesis Bago S.A., BioVaxys Technology Corporation, Boehringer Ingelheim International GmbH, Brilliant Bio Pharma Private limited, Ceva Sante Animale, China Animal Husbandry Industry Co., Ltd., Dalan Animal Health, Elanco Animal Health Inc., Endovac Animal Health, LLC by Immvac Inc., Hester Biosciences Limited, HIPRA, S.A., Indian Immunologicals Limited, Kemin Industries, Inc., Merck KGaA, Neogen Corporation, Phibro Animal Health Corporation, SAN Vet Holding GmbH, Sanofi S.A., Seppic S.A., Torigen Pharmaceuticals Inc., Vaxxinova GmbH, VEROVACCiNES GmbH, Vetigenics, LLC, Vetoquinol SA, Virbac, Inc., and Zoetis Inc.. Actionable Recommendations for Industry Leaders

For industry leaders operating in the animal vaccines market, several actionable recommendations are emerging from this comprehensive analysis. First, it is imperative to invest strategically in research and development initiatives that embrace novel vaccine technologies such as mRNA and recombinant platforms. Emphasizing collaborative studies with research institutions and leveraging digital health solutions can streamline development timelines and enhance vaccine efficacy. Capitalizing on data analytics to monitor post-market performance will also support targeted improvements in existing formulations.

Furthermore, strategic portfolio diversification across various product types addresses the distinct needs of both companion and livestock animals. Companies should consider integrating product development strategies that align with comprehensive disease coverage, ranging from bacterial to viral infections. Such diversification not only mitigates risk but also offers new revenue streams by addressing niche market demands.

Enhancing the efficiency of vaccine delivery channels is another key recommendation. Whether deploying injectable vaccines across intramuscular, intravenous, and subcutaneous routes or optimizing oral vaccine formulations, focusing on logistical and clinical efficiencies remains critical. In addition, refining distribution strategies across online platforms, retail pharmacies, and veterinary clinics can improve market penetration and consumer accessibility.

Finally, maintain adaptable regulatory and market strategies that respond dynamically to global trends. This includes proactive engagement with regulatory authorities to ensure alignment with evolving standards, especially in regions with rapidly changing market conditions. By fostering strategic alliances and pursuing regional customization of products and services, industry leaders can better position their organizations to capitalize on emerging opportunities and navigate the complexities of a dynamic global marketplace.

Conclusion and Future Outlook

In conclusion, the animal vaccines market is undergoing a period of significant transformation that is being shaped by technological innovation, strategic segmentation, and dynamic regional factors. This evolving landscape presents both challenges and opportunities that require industry stakeholders to be agile, forward-thinking, and committed to continuous improvement. The in-depth analysis presented herein highlights the importance of embracing novel vaccine platforms and integrating nuanced insights from product, animal type, and disease segmentation to create targeted, effective solutions.

Looking forward, the drive towards digital health integration, coupled with an increased focus on regulatory compliance and strategic global partnerships, will define the pathway for sustained growth and innovation. The synthesis of these industry trends not only affirms the critical role of animal vaccines in achieving improved animal health outcomes but also underscores the broader implications for food safety, public health, and economic development. As decision-makers recalibrate their strategies, the insights provided in this report offer a robust foundation for navigating a complex but promising market landscape.

The future of animal vaccines is bright, bolstered by continuous advancements in technology and science. Stakeholders must remain vigilant and responsive to emerging trends, ensuring that their strategic initiatives are backed by rigorous research and a deep understanding of regional market dynamics. This commitment to adaptive and innovative practices will be the key to unlocking new opportunities and sustaining long-term success in the animal vaccines sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of zoonotic diseases worldwide
      • 5.1.1.2. Government initiatives promoting animal health care globally
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the R&D and production of animal vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging partnerships with wildlife conservation organizations
      • 5.1.3.2. Innovations in vaccine delivery methods enhancing administration and improving animal immune responses
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and approval processes associated with animal vaccines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing preference for attenuated live vaccines to protect against diseases with complex pathogen biology
    • 5.2.2. Animal Type: Rising significance of animal vaccines for companion animals owing to increasing pet ownership
    • 5.2.3. Disease Type: Increasing need for animal vaccines to deal with viral infections
    • 5.2.4. Route of Administration: Rising importance of IM vaccines owing to their quick absorption into the bloodstream
    • 5.2.5. Distribution Channel: Increasing preference for online pharmacies owing to growing adoption of digital platforms and convenience
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Animal Vaccines Market, by Product

  • 6.1. Introduction
  • 6.2. Inactivated Vaccines
  • 6.3. Live Attenuated Vaccines
  • 6.4. mRNA Vaccines
  • 6.5. Recombinant Vaccines
  • 6.6. Subunit Vaccines

7. Animal Vaccines Market, by Animal Type

  • 7.1. Introduction
  • 7.2. Companion Animals
    • 7.2.1. Cats
    • 7.2.2. Dogs
  • 7.3. Livestock Animals
    • 7.3.1. Cattle
    • 7.3.2. Poultry
    • 7.3.3. Sheep
    • 7.3.4. Swine

8. Animal Vaccines Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Bacterial Infections
    • 8.2.1. Clostridial
    • 8.2.2. E. Coli
    • 8.2.3. Leptospirosis
    • 8.2.4. Pasteurella
  • 8.3. Fungal Infections
  • 8.4. Parasitic Infections
    • 8.4.1. Ectoparasites
    • 8.4.2. Endoparasites
  • 8.5. Viral Infections
    • 8.5.1. Avian Influenza Virus
    • 8.5.2. Bovine Viral Diarrhea Virus (BVDV)
    • 8.5.3. Foot-and-Mouth Disease Virus (FMDV)
    • 8.5.4. Newcastle Disease Virus
    • 8.5.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 8.5.6. Rabies Virus

9. Animal Vaccines Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Injectable Vaccines
    • 9.2.1. Intramuscular (IM)
    • 9.2.2. Intravenous (IV)
    • 9.2.3. Subcutaneous (SC)
  • 9.3. Oral Vaccines

10. Animal Vaccines Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Veterinary Clinics

11. Americas Animal Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Animal Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Animal Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Anivive secures USD 20 million investment from Leonid Capital Partners to develop the next generation of pet health
    • 14.3.2. Boehringer Ingelheim unveils next-gen vaccine in India, tackling rising Marek's disease challenges
    • 14.3.3. BioVaxys and SpayVac expand vaccine production to advance wildlife contraception and aquaculture solutions
    • 14.3.4. Ceva Animal Health expands vaccine production with new Hungarian facility
    • 14.3.5. Merck Animal Health unveils RNA-particle feline vaccine to target feline leukemia virus
    • 14.3.6. Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
    • 14.3.7. University of Missouri's innovative vaccine offers new hope against bovine anaplasmosis
    • 14.3.8. ICAR-CIBA and Indian Immunologicals Limited entered into an agreement for commercial development of fish vaccine
    • 14.3.9. Fischer MV partners with BAV to launch livestock and aquaculture vaccines in India
    • 14.3.10. Merck Animal Health's strategic acquisition of Elanco's aqua business enhances vaccine and treatment portfolio in aquaculture sector
    • 14.3.11. Huvepharma's EUR 72 million investment in Bulgarian veterinary vaccine plant to enhance global supply chain
    • 14.3.12. Pioneering partnership enhances African swine fever vaccine development for global pig protection
    • 14.3.13. Zoetis invests AUD 350 million to amplify vaccine production in Australia, bolstering animal health and industry collaboration
    • 14.3.14. Virbac's strategic acquisition of Sasaeah boosts its market position and innovation in Japan's animal vaccine market
    • 14.3.15. Zendal and CSIC introduce innovative DNA vaccine to combat leishmaniasis
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Virbac, Inc.
    • 14.4.2. Phibro Animal Health Corporation
    • 14.4.3. Ceva Sante Animale
    • 14.4.4. Boehringer Ingelheim International GmbH

Companies Mentioned

  • 1. Biogenesis Bago S.A.
  • 2. BioVaxys Technology Corporation
  • 3. Boehringer Ingelheim International GmbH
  • 4. Brilliant Bio Pharma Private limited
  • 5. Ceva Sante Animale
  • 6. China Animal Husbandry Industry Co., Ltd.
  • 7. Dalan Animal Health
  • 8. Elanco Animal Health Inc.
  • 9. Endovac Animal Health, LLC by Immvac Inc.
  • 10. Hester Biosciences Limited
  • 11. HIPRA, S.A.
  • 12. Indian Immunologicals Limited
  • 13. Kemin Industries, Inc.
  • 14. Merck KGaA
  • 15. Neogen Corporation
  • 16. Phibro Animal Health Corporation
  • 17. SAN Vet Holding GmbH
  • 18. Sanofi S.A.
  • 19. Seppic S.A.
  • 20. Torigen Pharmaceuticals Inc.
  • 21. Vaxxinova GmbH
  • 22. VEROVACCiNES GmbH
  • 23. Vetigenics, LLC
  • 24. Vetoquinol SA
  • 25. Virbac, Inc.
  • 26. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. ANIMAL VACCINES MARKET MULTI-CURRENCY
  • FIGURE 2. ANIMAL VACCINES MARKET MULTI-LANGUAGE
  • FIGURE 3. ANIMAL VACCINES MARKET RESEARCH PROCESS
  • FIGURE 4. ANIMAL VACCINES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANIMAL VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 233. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. TAIWAN ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 244. TAIWAN ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 251. THAILAND ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 252. THAILAND ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 253. THAILAND ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. THAILAND ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 255. THAILAND ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 262. VIETNAM ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 263. VIETNAM ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 264. VIETNAM ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. VIETNAM ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 266. VIETNAM ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 285. DENMARK ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 286. DENMARK ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 287. DENMARK ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. DENMARK ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 289. DENMARK ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 296. EGYPT ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 297. EGYPT ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 298. EGYPT ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. EGYPT ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 300. EGYPT ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. FINLAND ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 307. FINLAND ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 308. FINLAND ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 309. FINLAND ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 310. FINLAND ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 311. FINLAND ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. FRANCE ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 313. FRANCE ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. FRANCE ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 318. FRANCE ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 319. FRANCE ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 320. FRANCE ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 321. FRANCE ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 322. FRANCE ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 323. GERMANY ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 324. GERMANY ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. GERMANY ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 326. GERMANY ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 327. GERMANY ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. GERMANY ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 329. GERMANY ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 330. GERMANY ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 331. GERMANY ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 332. GERMANY ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 333. GERMANY ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 334. ISRAEL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 335. ISRAEL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. ISRAEL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 337. ISRAEL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 338. ISRAEL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. ISRAEL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 340. ISRAEL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 341. ISRAEL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 342. ISRAEL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 343. ISRAEL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 344. ISRAEL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 345. ITALY ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 346. ITALY